Reviewing Evofem Biosciences (EVFM) & Akebia Therapeutics (AKBA)

Evofem Biosciences (NASDAQ:EVFM) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Profitability

This table compares Evofem Biosciences and Akebia Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evofem Biosciences N/A N/A -1,461.62%
Akebia Therapeutics -30.60% -46.95% -17.53%

Valuation and Earnings

This table compares Evofem Biosciences and Akebia Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Evofem Biosciences N/A N/A -$9.99 million N/A N/A
Akebia Therapeutics $177.98 million 2.59 -$76.91 million ($1.77) -4.57

Evofem Biosciences has higher earnings, but lower revenue than Akebia Therapeutics.

Volatility and Risk

Evofem Biosciences has a beta of 2.85, indicating that its share price is 185% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Evofem Biosciences and Akebia Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evofem Biosciences 0 0 5 0 3.00
Akebia Therapeutics 0 1 6 0 2.86

Evofem Biosciences presently has a consensus target price of $10.40, suggesting a potential upside of 197.14%. Akebia Therapeutics has a consensus target price of $20.00, suggesting a potential upside of 147.22%. Given Evofem Biosciences’ stronger consensus rating and higher possible upside, research analysts clearly believe Evofem Biosciences is more favorable than Akebia Therapeutics.

Insider & Institutional Ownership

79.3% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 75.3% of Akebia Therapeutics shares are owned by institutional investors. 3.4% of Evofem Biosciences shares are owned by insiders. Comparatively, 8.2% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Evofem Biosciences beats Akebia Therapeutics on 7 of the 11 factors compared between the two stocks.

Evofem Biosciences Company Profile

Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women. The company is also developing vaginal gel product candidate for the treatment of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients. The company is also developing a HIF-based portfolio of product candidates, such as AKB-5169, a preclinical compound for the treatment of inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds internationally. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply